Retatrutide (Reta) in the UK: what we know so far

Is retatrutide approved or available in the UK?

The MHRA’s 24 July 2026 warning states that retatrutide is not authorised for use in the UK. A trial announcement is not a UK marketing authorisation. [1]

UK authorisation

Not authorised in the cited MHRA warning.

Confirmed UK launch date

No confirmed date established by the primary sources reviewed here.

Confirmed UK launch price

No verified UK launch price in this review.

SHIFT’s role

Explaining the evidence. No retatrutide supply or reservation service.

Keep the questions separate: a research result, an application to a regulator, authorisation, commercial supply and an NHS access decision are different things. Evidence of one does not establish the others.

What is retatrutide, and does “Reta” mean the same thing?

Retatrutide, development code LY3437943, is an investigational medicine being developed by Eli Lilly. Research describes a single molecule acting at the GIP, GLP-1 and glucagon receptors. Studies have used a once-weekly injection. [2] [6]

Reta is an informal shortened name used online. It is not evidence that a product bearing that name is an authorised medicine or the material used in a clinical trial. This guide uses the full research name so the sources are easier to check.

What does “triple agonist” mean?

An agonist activates a receptor. “Triple” here refers to GIP, GLP-1 and glucagon; it is not a claim that an effect is three times stronger. Lilly also distinguishes this description from the inaccurate nickname “GLP-3”. [6]

A mechanism is a reason to study a medicine, not a shortcut to its clinical verdict. To assess a claimed benefit, look for a measured outcome in people, an appropriate comparator and safety results. An extra receptor target does not, by itself, answer whether something is more effective, easier to tolerate or suitable for an individual.

What do the retatrutide trial results show?

The evidence below separates a peer-reviewed trial from manufacturer-reported Phase 3 findings. These are selected results, not a complete systematic review.

Research-dose labels identify trial groups, not doses to use. No dosing, escalation or self-injection instructions are provided here.

In TRIUMPH-1, Lilly reported discontinuation because of adverse events in 11.3% of the 12 mg group and 4.9% of the placebo group. Keep tolerability beside efficacy when reading the table. [4]

Why do two analyses give different percentages?

The efficacy estimand asks what the effect would be with continued study treatment and without prohibited weight-management treatments. The treatment-regimen estimand includes outcomes regardless of adherence or use of those treatments. They answer different questions within the same trial. [3]

Neither is a promise about the next person who reads an article. Ask which analysis a headline uses before comparing it with another headline.

What is the TRIUMPH programme?

TRIUMPH is Lilly’s retatrutide clinical-trial programme, not a SHIFT programme. TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 studied different groups, as set out above. The original reports identify the respective studies as NCT05929066, NCT05929079 and NCT05882045. [3] [5]

On 6 June 2026, Lilly reported additional TRIUMPH-1 findings at the American Diabetes Association meeting, alongside the separate TRANSCEND-T2D-1 study. The latter concerned type 2 diabetes and should not be presented as another analysis of the obesity master trial. [4]

Next announced evidence checkpoint: Lilly’s 15 September announcement schedules a retatrutide symposium for 30 September at EASD 2026. On this guide’s source-check date, that presentation is still in the future. An announced presentation is not newly available full results. [8]

How should I interpret the weight-loss figures?

A study average is not an individual forecast. In particular, do not select a percentage from a higher-dose group, multiply it by your weight and treat the result as an expected outcome.

The reported 30.3% finding at 104 weeks comes from an extension with eligibility conditions: participants had completed the main study and tolerated their assigned treatment, and had a qualifying baseline BMI. That is not the same group as everyone originally randomised. [4]

For any result, ask: Who was eligible? Who was excluded? How long were people followed? What happened to those who stopped? What was the comparison? Were the results peer-reviewed, or is the source a sponsor announcement? Those questions make a percentage useful rather than merely eye-catching.

What side effects have been reported?

Lilly’s TRIUMPH-1 report includes nausea, diarrhoea, constipation, vomiting and altered skin sensations, called dysesthesia. In the 12 mg group, nausea was reported in 42.4% versus 14.8% with placebo; vomiting in 25.3% versus 4.8%. These are selected adverse events, not a complete safety profile. [4]

Do not interpret “usually mild to moderate” as “cannot be serious”, or a trial average as an assessment of your own symptoms. Side-effect reporting, discontinuations and longer-term follow-up all matter when weighing evidence.

Does it protect the heart?

TRIUMPH-3’s reported cardiovascular-event estimates had confidence intervals spanning no difference. These findings do not establish a definite reduction in heart attacks or strokes. Changes in risk factors should not be substituted for demonstrated reductions in clinical events. [5]

Does it preserve muscle?

This guide does not establish a muscle-building or muscle-preservation benefit. Such a claim would need directly relevant body-composition or strength evidence. A description of three receptor targets is not that evidence, and separate research into muscle-targeting treatments should not be attributed to retatrutide.

What about “Reta peptides”, pens or vials sold online?

The MHRA warns against products sold as retatrutide and describes concerns about unregulated medicines’ quality and safety. A label or seller’s certificate does not establish UK authorisation. [1]

Research reporting should not become a shopping guide for an unapproved product. This page therefore contains no seller recommendations, affiliate buying links, preparation instructions or reconstitution calculator. Someone concerned about a product they have used should seek professional advice and can consult the MHRA’s reporting information. [1]

How much will retatrutide cost in the UK?

This review has not verified a UK launch price. Prices advertised for products sold online do not tell us what an authorised future treatment would cost. A predicted figure is not made more reliable by placing “UK” beside it.

If a legitimate UK price is announced later, a useful comparison would need the supply duration, formulation, required consultation and any compulsory charges. Until then, there is no defensible price table for this guide to publish.

Will retatrutide be available on the NHS?

No routine NHS retatrutide pathway is established by the sources reviewed here. Authorisation and an NHS access decision are separate questions. The NHS explains that weight-management care can involve lifestyle support, selected medicines and, for some people, specialist assessment or surgery. [7]

Do not apply another medicine’s eligibility rules to retatrutide or assume a private launch would mean immediate NHS access. A future answer would need a specific, dated decision for the relevant NHS system.

Is there a confirmed retatrutide UK release date?

Lilly’s July announcement describes a planned US regulatory submission in the first quarter of 2027. That is a company plan to apply, not an approval or a UK release date. [5]

Our update rule is straightforward: report a dated decision once it exists, identify the country and regulator, and explain exactly what changed. A projected study completion, conference presentation or filing must not be rewritten as “available from” a particular month.

Retatrutide versus Mounjaro: what is a fair comparison?

Retatrutide and Mounjaro’s active ingredient, tirzepatide, are different molecules. Their receptor profiles differ; that description alone cannot establish which produces a better overall outcome for an individual. [6]

A useful comparison should put the population, treatment duration, comparator, analysis method and adverse effects side by side. To make a claim about superiority, look for directly relevant comparative evidence rather than choosing the largest percentages from separate studies. This guide makes no head-to-head superiority claim and is not a recommendation to switch treatment.

Retatrutide versus Wegovy: avoid the percentage contest

Wegovy’s active ingredient, semaglutide, acts through GLP-1; retatrutide is being studied as a triple receptor agonist. [6] The same comparison questions apply: Who was studied, against what, for how long, and with what harms or discontinuations?

“More receptors” and “a larger result in another trial” are not substitutes for an individual assessment. A research-stage medicine should not be presented as an available replacement for someone’s current care.

Can a medicine trial be compared with weight-loss surgery?

A superficially similar weight percentage does not make two interventions equivalent. Any fair assessment would also need the populations, follow-up, complications, subsequent care and outcomes beyond weight. The NHS describes surgery as a treatment requiring specialist consideration, not simply a percentage target. [7]

Should I wait for a future medicine?

This guide cannot decide what care you need now. Discuss your current concerns with an appropriately qualified health professional rather than treating an uncertain future launch as a personal treatment plan. A useful question is: “What are my appropriate options now, and what would genuinely change that decision later?”

Where can I find information about current care?

The NHS overview of overweight and obesity explains current approaches and how to seek help. For background reading on hormone pathways, use our GLP-1 Knowledge Centre. These are reading routes, not an offer of retatrutide.

What about support without medication?

The NHS includes eating, activity and behavioural support within weight-management care. [7] Discuss what is appropriate and sustainable for your circumstances. “Medication-free” does not need to mean doing everything alone, and reading research does not commit you to taking a medicine.

Questions worth asking before believing a headline

• Does the source refer to retatrutide itself, or a different medicine or combination?
• Is this a regulator’s decision, an original paper, a sponsor announcement or someone else’s interpretation?
• Are benefits and adverse effects reported for the same population and follow-up?
• Are trial completers being presented as though they represent everyone who started?
• Does a claim about men have relevant sex-specific evidence? Inclusion of men in a trial is not proof of a benefit unique to men.
• Is an article explaining research, or quietly directing me towards a seller?

For context, 51.8% of participants in the published Phase 2 obesity trial were men. That does not make it a men-only trial or establish a male-specific treatment recommendation. [2]

Retatrutide UK: common questions

Is Reta a different medicine from retatrutide?

Reta is an informal shortened name. A product using that name is not thereby verified as an authorised medicine.

Is retatrutide authorised in the UK?

The MHRA’s 24 July 2026 warning says it is not authorised for UK use. Check the dated regulator source for changes.

Is it called GLP-3?

Lilly describes GLP-3 as an inaccurate nickname. Retatrutide acts at GIP, GLP-1 and glucagon receptors.

Are the trial percentages guaranteed results?

No. They describe study analyses in particular populations, not individual forecasts. The analysis method and adverse effects matter.

Is there a UK launch date or price?

This review has not established a confirmed UK launch date or price. A planned US application is neither.

Can SHIFT supply or reserve retatrutide?

No. This is an informational guide, not a supply, reservation or waiting-list service.

Sources for these answers and the fuller context are in the relevant sections above and the reference list below.

The SHIFT take

A short checklist to keep

• Check UK status at the regulator source.
• Read trial benefits and adverse effects together.
• Identify the population, duration and analysis.
• Do not confuse a submission plan with a launch.
• Take individual treatment questions to a qualified professional.

Primary sources and update record

Sources checked on 23 September 2026. Manufacturer announcements are labelled as such; listing a source is not a claim of endorsement or a substitute for clinical review. The 2023 paper is included as historical evidence, not as a current approval statement.

1. MHRA: UK retatrutide warning, 24 July 2026.
2. Jastreboff and colleagues: Phase 2 obesity trial, New England Journal of Medicine, 26 June 2023. Peer-reviewed original research.
3. Lilly: TRIUMPH-1 topline results, 21 May 2026. Manufacturer report.
4. Lilly: additional TRIUMPH-1 and TRANSCEND-T2D-1 findings, 6 June 2026. Manufacturer report.
5. Lilly: TRIUMPH-2 and TRIUMPH-3 topline results and US submission plan, 23 July 2026. Manufacturer report.
6. Lilly: retatrutide mechanism and terminology explainer, reviewed July 2026. Developer information.
7. NHS: overweight and obesity overview. General UK care information.
8. Lilly: EASD presentation announcement, 15 September 2026. Future presentation notice at the source-check date.

This revision: clarifies research terminology, separates trial analyses, adds the newer evidence checkpoint and makes the informational purpose explicit. Source checks and substantive publication changes are recorded separately; dates should not be advanced merely to make the page look fresh.

Return to the Knowledge hub · Read the GLP-1 background guide